July 11, 2025 11:52 am
Glenmark Pharma Stocks Today: The stock surged 9.99 per cent to hit its 52-week high as well as the upper circuit limit of Rs 2,095.65 on the BSE.
February 22, 2024 4:31 pm
Ryaltris is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age.
August 06, 2021 1:30 pm
Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals, is a leading developer and manufacturer of select high-value, non-commoditised Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas.
August 03, 2021 9:28 pm
Glenmark Life Sciences IPO allotment status: Initial public offering (IPO) of Glenmark Life Sciences, the wholly-owned subsidiary of Glenmark Pharmaceuticals, was subscribed 44.17 times and the shares will now get allotted to investors. Here's how to check if you have been allotted the shares.
July 30, 2021 9:45 am
Glenmark Life Sciences IPO subscription status: Glenmark Life Sciences IPO was subscribed 44.17 times on the final day of the offer.
July 20, 2020 1:23 pm
Glenmark Pharmaceuticals stock declined 5.10 per cent to Rs 408 on the BSE and at the NSE, it tanked 5.75 per cent to Rs 405.
June 22, 2020 1:25 pm
The scrip jumped 19.99 per cent to Rs 490.90 -- its upper circuit limit -- on the BSE. On the NSE, it zoomed 19.99 per cent to Rs 491.20 -- its highest permissible trading limit for the day.
April 30, 2020 2:03 pm
The Mumbai-based company is the first pharmaceutical company in India to be given an approval by the regulator to start the trial on COVID-19 patients in the country.
April 30, 2020 1:26 pm
The scrip jumped 8.88 per cent to Rs 359 on the BSE. On the NSE, it zoomed 8.88 per cent to Rs 359.
July 17, 2018 1:47 pm
The company's current portfolio consists of 138 products authorised for distribution in the US market, and 62 Abbreviated New Drug Applications (ANDAs) are pending approval with the USFDA.


